

ASX Announcement

30 May 2022



Emyria Investor Webinar, June 1st

Emyria Limited (ASX: EMD) (Emyria or the Company), a clinical stage biotechnology company leveraging real-world patient data to develop treatments for unmet needs, is pleased to invite shareholders to an overview of the Phase 1 trial data for EMD-RX5, Emyria's proprietary ultra-pure CBD capsule and novel MDMA-analogue drug discovery pipeline to be held on the: **Wednesday 1st June at 11:00 am AEST.**

Emyria's Managing Director and CEO, Dr. Michael Winlo will present the recently announced positive Phase 1 trial data for the **EMD-RX5** crossover study with Epidyolex®, the only TGA and FDA registered CBD medicine, indicating excellent bioavailability, safety and tolerability among 12 healthy and demographically diverse volunteer subjects.

Details of the event are as follows:

- **Event:** Emyria Drug Development Webinar
- **Webinar Presenter:** Emyria's Managing Director and CEO, Dr. Michael Winlo
- **Date and Time:** Wednesday 1st June, 11:00am Sydney time (AEST)
- **Where:** Zoom Webinar - details to be provided upon registration

To register, please click on the link below:

<https://janemorganmanagement-au.zoom.us/j/81626179616>

After registering your interest, you will receive a confirmation email with information about joining the webinar. Participants will be able to submit questions via the panel throughout the presentation, however, we encourage shareholders and investors to send through questions via email beforehand to Lexi O'Halloran at: lexi@janemorganmanagement.com.au

This announcement has been approved and authorised for release by the Managing Director of Emyria Limited

For further information:

Dr. Michael Winlo
Managing Director
+61 (0) 8 6559 2800
mwinlo@emyria.com

Lexi O'Halloran
Media/Investor Relations
+ 61 (0) 404 577 076
lexi@janemorganmanagement.com.au

Andrew Williams
Media Relations
+61 (0) 412 614 125
awilliams@emyria.com



About Emyria (www.emyria.com)

Emyria Limited develops biopharmaceuticals guided by proprietary Real-World Data collected with patients across its wholly-owned clinical service subsidiary, Emerald Clinics.

Emyria's current clinical development programs are focussed on the registration of proprietary formulations of cannabinoid-based medical treatments (CBMTs) and novel MDMA ('ecstasy') analogues with major global regulators. Emyria's programs target major unmet needs such as mental health disorders and chronic pain.

Emyria's Real World Data (RWD) guides each of Emyria's clinical development programs and care models. Emyria RWD is deep, ethically-sourced clinical evidence gathered with thousands of patients who also receive personalised care at Emerald Clinics.

Emyria is therefore uniquely providing care to patients, generating clinical evidence and advancing multiple proprietary treatment programs towards registration.

Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, the company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.